The median ERBB2 copy number was also higher in the prior anti-EGFR group (5.02; range: 0.0–102.1), although the difference did not reach statistical significance ( Figure 2 ).
← all excerpts
Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway.
1
—
—